WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001087336) CANCER TREATMENTS BY USING A COMBINATION OF AN ANTIBODY AGAINST HER2 AND INTERLEUKIN -2
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/087336    International Application No.:    PCT/US2001/015525
Publication Date: 22.11.2001 International Filing Date: 15.05.2001
Chapter 2 Demand Filed:    10.12.2001    
IPC:
A61K 39/395 (2006.01), C07K 16/32 (2006.01)
Applicants: HEALTH RESEARCH, INC. [US/US]; Roswell Park Cancer Institute Division, Elm and Carlton Streets, Buffalo, NY 14263 (US) (For All Designated States Except US).
ARCH DEVELOPMENT CORPORATION [US/US]; 5640 S. Ellis Avenue, Suite 405, Chicago, IL 60637 (US) (For All Designated States Except US).
CALIGIURI, Michael, A. [US/US]; (US) (For US Only).
MEROPOL, Neal, J. [US/US]; (US) (For US Only).
SCHILSKY, Richard, L. [US/US]; (US) (For US Only)
Inventors: CALIGIURI, Michael, A.; (US).
MEROPOL, Neal, J.; (US).
SCHILSKY, Richard, L.; (US)
Agent: HENRY, Leslie, T.; Alston & Bird LLP, Bank of America Plaza, 101 South Tryon Street, Suite 4000, Charlotte, NC 28280-4000 (US)
Priority Data:
60/204,284 15.05.2000 US
09/855,342 14.05.2001 US
Title (EN) CANCER TREATMENTS BY USING A COMBINATION OF AN ANTIBODY AGAINST HER2 AND INTERLEUKIN -2
(FR) TRAITEMENT DE CANCERS PAR UTILISATION D'UNE COMBINAISON D'UN ANTICORPS ANTI HER2 ET D'UNE INTERLEUKINE 2
Abstract: front page image
(EN)Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.
(FR)La présente invention concerne des procédés de traitement d'un sujet atteint d'un cancer se caractérisant par la surexpression de la protéine de récepteur HER2, au moyen d'une combinaison d'interleukine 2 (IL-2) ou d'une de ses variantes, et d'au moins un anticorps anti-HER2 ou fragment de celui-ci. Ces agents anti-tumoraux sont administrés sous forme de deux compositions pharmaceutiques séparées, l'une contenant l'interleukine 2 (IL-2) (ou variante), l'autre contenant au moins un anticorps anti-HER2 (ou fragment), selon une posologie donnée. L'administration de ces deux agents permet de renforcer l'efficacité de l'anticorps anti-HER2 seul, ce qui permet d'obtenir une réponse thérapeutique positive qui est supérieure à celle observée avec cet agent anti-tumoral.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)